Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Emily Stenke und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Pediatric Gastroenterology, Children's Health Ireland at Crumlin, Dublin, Ireland. Hauptthemen laut MEDLINE: Infliximab, Drug Monitoring, Gastrointestinal Agents, Crohn Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Children's Medical and Research Foundation, Ireland, Children’s Medical and Research Foundation, Ireland.
Abstract (Originalsprache)
Background
Proactive drug monitoring in our national cohort of children with inflammatory bowel disease suggested that 5 mg/kg dosing of infliximab (IFX) was associated with inadequate trough levels (TLs), thus we commenced empiric 10 mg/kg dosing in 2019.
Methods
This was a retrospective study of patients commenced on 5 or 10 mg/kg IFX between 2018 and 2020. The primary outcome was pre-fourth TL ≥5 µg/mL. Data source verification and analysis were undertaken retrospectively.
Results
During the study period, 122 patients were commenced on IFX and eligible for inclusion. Of these, 72% were male, 76% had Crohn’s disease (CD), 23% had ulcerative colitis; mean (standard deviation [SD]) age at diagnosis was 11.8 (2.7) years; 60 commenced 5 mg/kg. Baseline parameters were comparable between groups. Fewer patients in the 5 mg/kg than 10 mg/kg group had pre-fourth TLs ≥5 µg/mL (6/48 [12.5%] vs 28/50 [56%], P < .001; mean [SD] TL 3.5 [6.3] vs 10.0 [9.9], P < .001). The 5 mg/kg group was less likely to have target pre-third TLs (6% vs 80%, P < .001); more likely to have treatment escalation (78% vs 45%, P < .001), and less likely to de-escalate (10% vs 29% P = .008). Proactive therapeutic dose monitoring (TDM) was practiced throughout the study period and mean (SD) IFX exposure per kg/week was similar in both groups by 1 year (1.4 [0.43] vs 1.56 [0.56] mg/kg/week, P = .137), as were infliximab durability and clinical outcomes.
Conclusions
Our real-world data show that 5 mg/kg infliximab induction does not achieve target TLs in most children with CD. Higher-dose regimens should be considered, especially if proactive therapeutic drug monitoring is not available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Centre for Pediatric Gastroenterology, Children's Health Ireland at Crumlin, Dublin, Ireland.
- The DOCHAS Study, Children's Health Ireland at Crumlin, Dublin, Ireland.
- School of Medicine, University College Dublin, Dublin, Ireland.
- Department of Pediatrics, Royal College of Surgeons of Ireland, Dublin, Ireland.
ORCID-Profile: Emily Stenke, Shoana Quinn, Annemarie Broderick, Emer Fitzpatrick, Billy Bourke, Lorraine Stallard, Séamus Hussey
Förderung
- Children's Medical and Research Foundation, Ireland
- Children’s Medical and Research Foundation, Ireland
Zitieren
APA
Stenke, E., Alhassan, D., Moclair, M., Cooper, S., Dominika, A., Lang, C., Quinn, S., Broderick, A., Fitzpatrick, E., Bourke, B., Stallard, L., & Hussey, S. (2025). Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf031
Vancouver
Stenke E, Alhassan D, Moclair M, Cooper S, Dominika A, Lang C, et al. Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf031
BibTeX
@article{Stenke2025,
author = {Stenke, Emily and Alhassan, Dahlal and Moclair, Molly and Cooper, Sarah and Dominika, Anna and Lang, Ciara and Quinn, Shoana and Broderick, Annemarie and Fitzpatrick, Emer and Bourke, Billy and Stallard, Lorraine and Hussey, Séamus},
title = {Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf031}
}
EUVIMED